How long does TB-500 take to work in the research?

In the foundational rat dermal-wound study, thymosin β4 increased re-epithelialisation by 42% over controls by day 4 and 61% by day 7, and a more-active analogue reached 50% wound closure as early as day 3 — so the early dermal window in animals is measured in days, not weeks. But these are skin-wound observations in rodents, and most of them describe full-length Tβ4 rather than the TB-500 fragment. There is no verified human muscle-or-tendon results timeline for TB-500, and this page does not provide one.

Is there a human timeline for TB-500?

Only in indications unrelated to muscle recovery. The parent peptide thymosin β4 has human trial data in dermal ulcers — Phase 2 studies reported healing accelerated by almost a month in patients who healed — and in eye-surface disease, where a Phase 3 trial of the Tβ4 eye-drop RGN-259 showed complete corneal healing at four weeks in six of ten treated patients. There is no human musculoskeletal-healing trial, so any page giving you a confident week-by-week muscle-recovery schedule for TB-500 is inventing it.

Why is TB-500 different from thymosin β4 here?

TB-500 is a synthetic fragment associated with the actin-binding region of thymosin β4, but the overwhelming majority of the published wound-healing, cardiac and dermal-ulcer evidence was generated with full-length Tβ4, not the fragment. A 2025 scoping review of the literature found that direct TB-500-specific evidence was limited to essentially a single study. That is why an honest timeline has to be labelled as Tβ4 data — extrapolating it to the fragment is an assumption, not a demonstrated result.

Does the timeline depend on the type of injury?

Yes, and heavily. The concrete day-by-day figures come from skin wounds, while the human trial data comes from ulcers and the cornea — each tissue heals on its own clock and passes through the inflammatory, proliferative and remodelling phases at different rates. Because there is no controlled tendon, ligament or muscle timeline for TB-500 at all, there is no single 'TB-500 works in X days' figure that holds across injuries.

Is TB-500 approved for human use?

No. TB-500 is an investigational compound without regulatory approval as a therapeutic. Its parent peptide thymosin β4, in the eye-drop formulation RGN-259, holds orphan-drug designation and has completed Phase 2 and Phase 3 ophthalmic trials, but no FDA marketing approval has been granted as of 2026. Titan Peptide Lab supplies TB-500 strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and nothing on this page is medical or dosing advice.

TB-500 · time-course · research use only

How long does TB-500 take to work? What the preclinical time-course actually shows.

This is one of the most-searched TB-500 questions, and the honest answer has two layers most vendor pages skip. First: like BPC-157, TB-500 has no large human trial with a week-by-week musculoskeletal results curve, so there is no verified 'it works in X days for muscle or tendon' figure to quote. Second, and more specific to this compound: a 2025 scoping review found that most of the published repair evidence is for full-length thymosin β4 (Tβ4) — the 43-amino-acid parent molecule — rather than the TB-500 fragment sold for research, with direct TB-500 evidence limited to essentially a single study. So the trajectory below is built from the Tβ4 literature and labelled honestly as such. What that literature does contain is a well-characterised dermal-wound time-course in rodents — measured at fixed days with concrete percentages — plus human data confined to eye-surface and skin-ulcer trials. This page reproduces that as a research reference: the three phases of tissue repair, the fixed assessment days in the foundational dermal study, where the human evidence actually sits, and why none of it translates to a muscle-recovery countdown. It is a summary of published research, not a human-use protocol or medical advice.

TB-500 5mg vial — $89.99 TB-500 dosage & reconstitution

Healing happens in three phases, not on one clock

Soft-tissue repair in the Tβ4 wound models moves through three overlapping phases: an inflammatory phase where the peptide is reported to dampen excessive inflammation while keeping appropriate immune-cell recruitment; a proliferative phase where it promotes keratinocyte and fibroblast migration, collagen deposition and angiogenesis; and a remodelling phase where treated wounds show better-organised collagen and reduced scarring. Because Tβ4's headline mechanism is accelerating cell migration, its effects appear across all three phases rather than at one moment — so 'how long does it take' depends entirely on which phase, and which tissue, you are measuring.

TB-500 half-life explained →

The fixed days in the foundational dermal study

The most-cited model is a rat full-thickness wound. In the foundational 1999 study (Malinda et al., Journal of Investigative Dermatology), topical or intraperitoneal Tβ4 increased re-epithelialisation by 42% over saline controls at day 4 and by as much as 61% at day 7 post-wounding, with treated wounds contracting at least 11% more than controls by day 7, alongside increased collagen deposition and angiogenesis. In a cell-migration assay, keratinocyte migration was stimulated two-to-three-fold within four to five hours. Those fixed days and percentages are the closest thing the compound has to a published dermal 'timeline'.

See the research dosing →

A faster analogue closed wounds by day 3

In a separate rat study using 8 mm punch wounds and twice-daily topical dosing over ten days, a more-active dimeric version of Tβ4 reached 50% wound closure as early as day 3, roughly one day ahead of standard Tβ4 and about three days ahead of the plain-gel control — with the standard-Tβ4 and control groups catching up by days seven and nine. It is a useful marker of how compressed the early dermal window can be in animals, while also showing that the exact 'day it works' shifts with the molecule, the dose and the formulation.

TB-500 + BPC-157 stack →

The human data is real — but it is eyes and skin ulcers, not muscle

TB-500's parent molecule does have human trial data, which is more than many research peptides can claim — but it sits in indications unrelated to the muscle-and-tendon recovery most people are searching for. In two Phase 2 dermal-ulcer trials (venous stasis and pressure ulcers), Tβ4 was reported to accelerate healing by almost a month in patients who healed, with roughly a quarter of one 73-patient venous-ulcer cohort healing completely within three months. In an ophthalmic Phase 3 trial of the Tβ4 eye-drop RGN-259, complete corneal healing occurred after four weeks in six of ten treated patients versus one of eight on placebo. None of these is a musculoskeletal timeline.

TB-500 vs BPC-157 →

Why 'when' can't be translated to a muscle-recovery number

Every animal figure here comes from dermal-wound models, and the human figures come from eye-surface and skin-ulcer trials — none of them a controlled muscle, tendon or ligament study, which do not yet exist for TB-500 with human efficacy endpoints. On top of that, most of the evidence base describes full-length Tβ4 rather than the TB-500 fragment specifically. So any confident 'TB-500 heals your injury in X weeks' claim is extrapolating across two gaps at once: from a different tissue, and from a different molecule. The literature tells you what Tβ4 did in controlled models; it is not a prediction of what any person's recovery would look like, and this page does not provide one.

Research-use policy →

Research-use framing

Every result on this page describes outcomes observed in preclinical animal studies or in clinical trials of the parent peptide thymosin β4, reproduced as a research reference for laboratory and in-vitro modelling — not as instructions for human use and not as a claim of efficacy for the TB-500 fragment in people. TB-500 is an investigational compound without regulatory approval as a therapeutic. Titan supplies it strictly as a research reagent, not for human or animal consumption, and nothing here is medical or dosing advice.

Lab testing & COA workflow →

The detail, in plain terms

The TB-500 / thymosin β4 time-course, at a glance.

Reference points drawn from the published preclinical dermal-wound literature on thymosin β4 and from human trials of the parent peptide, reproduced as a research reference. These are animal-study and ophthalmic/dermal-ulcer observations — not muscle-recovery results, not TB-500-fragment-specific efficacy, and not human predictions. Fixed days below are study assessment points, not a dosing schedule.

Human muscle/tendon timeline: None published. No controlled human musculoskeletal efficacy trial exists for TB-500; the muscle-recovery figures circulated online are not from human data.
TB-500 vs thymosin β4: Most published repair evidence is for full-length Tβ4, not the TB-500 fragment; a 2025 scoping review found direct TB-500 evidence limited to essentially a single study.
Dermal re-epithelialisation (rat): +42% vs saline controls at day 4 and +61% at day 7 in the foundational full-thickness wound study (Malinda et al., 1999).
Wound contraction (rat): At least 11% more contraction than controls by day 7, with increased collagen deposition and angiogenesis.
Cell migration (in vitro): Keratinocyte migration stimulated two-to-three-fold within 4–5 hours in a Boyden-chamber assay.
Fastest dermal marker: 50% wound closure by day 3 with a more-active dimeric Tβ4 analogue (8 mm punch wounds, twice-daily topical, 10-day study).
Human dermal-ulcer trials: Phase 2 venous-stasis / pressure-ulcer studies: healing accelerated by ~1 month in healers; ~25% of a 73-patient cohort fully healed within 3 months (84-day gel dosing).
Human ophthalmic trial (RGN-259): Phase 3 neurotrophic-keratopathy: complete corneal healing at 4 weeks in 6/10 treated vs 1/8 placebo; a distinct Tβ4 eye-drop drug, not research-grade TB-500.
Regulatory status: Not FDA-approved for any indication as of 2026; RGN-259 holds orphan-drug designation but has no marketing approval.

Questions researchers ask

Before you order.

How long does TB-500 take to work in the research?: In the foundational rat dermal-wound study, thymosin β4 increased re-epithelialisation by 42% over controls by day 4 and 61% by day 7, and a more-active analogue reached 50% wound closure as early as day 3 — so the early dermal window in animals is measured in days, not weeks. But these are skin-wound observations in rodents, and most of them describe full-length Tβ4 rather than the TB-500 fragment. There is no verified human muscle-or-tendon results timeline for TB-500, and this page does not provide one.
Is there a human timeline for TB-500?: Only in indications unrelated to muscle recovery. The parent peptide thymosin β4 has human trial data in dermal ulcers — Phase 2 studies reported healing accelerated by almost a month in patients who healed — and in eye-surface disease, where a Phase 3 trial of the Tβ4 eye-drop RGN-259 showed complete corneal healing at four weeks in six of ten treated patients. There is no human musculoskeletal-healing trial, so any page giving you a confident week-by-week muscle-recovery schedule for TB-500 is inventing it.
Why is TB-500 different from thymosin β4 here?: TB-500 is a synthetic fragment associated with the actin-binding region of thymosin β4, but the overwhelming majority of the published wound-healing, cardiac and dermal-ulcer evidence was generated with full-length Tβ4, not the fragment. A 2025 scoping review of the literature found that direct TB-500-specific evidence was limited to essentially a single study. That is why an honest timeline has to be labelled as Tβ4 data — extrapolating it to the fragment is an assumption, not a demonstrated result.
Does the timeline depend on the type of injury?: Yes, and heavily. The concrete day-by-day figures come from skin wounds, while the human trial data comes from ulcers and the cornea — each tissue heals on its own clock and passes through the inflammatory, proliferative and remodelling phases at different rates. Because there is no controlled tendon, ligament or muscle timeline for TB-500 at all, there is no single 'TB-500 works in X days' figure that holds across injuries.
Is TB-500 approved for human use?: No. TB-500 is an investigational compound without regulatory approval as a therapeutic. Its parent peptide thymosin β4, in the eye-drop formulation RGN-259, holds orphan-drug designation and has completed Phase 2 and Phase 3 ophthalmic trials, but no FDA marketing approval has been granted as of 2026. Titan Peptide Lab supplies TB-500 strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and nothing on this page is medical or dosing advice.